Item 8.01 Other Events.

On January 26, 2021, Vir Biotechnology, Inc. (the "Company") issued a press release announcing initial data from its ongoing Phase 1 clinical trial of VIR-3434 for chronic hepatitis B virus ("HBV") infection, which demonstrates significant and rapid reduction in HBV surface antigen. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

On January 27, 2021, the Company, Eli Lilly and Company ("Lilly") and GlaxoSmithKline plc ("GSK") issued a press release announcing that the first patient was dosed in Lilly's expanded BLAZE-4 clinical trial. Lilly has expanded its ongoing BLAZE-4 trial to evaluate the administration of bamlanivimab (LY-CoV555) 700mg with VIR-7831 (also known as GSK4182136) 500mg, two neutralizing antibodies that bind to different epitopes of the SARS-CoV-2 spike protein, in low-risk patients with mild to moderate COVID-19. A copy of the press release is attached hereto as Exhibit 99.2 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits



     Exhibit No.   Description

     99.1            Press Release of the Company, dated January 26, 2021.

     99.2            Press Release of the Company, dated January 27, 2021.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses